In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Featured Stories

The Other Pandemic

When Novo Nordisk’s anti-obesity medicine Wegovy launched in June 2021, patients and physicians could not get enough. As COVID-19 underscored the risks of obesity, along came the most effective drug yet – on a par with surgery, in terms of weight loss achieved. Pharma’s interest in this disease has reawakened, and Wegovy may be just the first of a new generation of more powerful anti-obesity medicines.

Innovation Strategy

Clive Dix: Industry Veteran, Vaccines Expert And Biotech Advocate

Clive Dix was awarded Scrip’s Lifetime Achievement honor jointly with his long-term colleague and friend Dame Kate Bingham in December 2021. With more than 30 years’ experience in pharma and biotech, Dix has seen the industry evolve and take on many challenges. He spoke to In Vivo about his career journey, the future of biotech and his expectations for 2022 – another year under the cloud of COVID-19.

Commercial Coronavirus COVID-19 Leadership

Five (Non-COVID) Clinical Trial Misses Of 2021

The coronavirus pandemic may have dominated the news in 2021, but industry’s more bread and butter R&D activities continued. Here, Scrip takes a look at five of the more notable clinical trial misses of the year that got readers clicking. 

Clinical Trials Companies Innovation

Putting The Patient First: The Challenge And Opportunities To Improve Rare-Disease Therapy Development


Advances in identifying the genetic causes of diseases, and particularly cancers, coupled with regulatory incentives to encourage the development of therapeutic approaches to once poorly managed orphan diseases have fueled a surge in exciting new medicines. To address some of these issues and explore potential solutions, Simbec-Orion in collaboration with Informa Pharma Intelligence convened a round table of experts attending the BIO International Convention

Read More

Growth Explore this Topic

Set Alert for Growth

Latest From Growth

Pharma Outlook 2022: What Next After A Year Of Innovation And Growth?

The biopharma industry broke records again in 2021 with the amount of money raised for drug development. After a year of rapid growth, what will 2022 bring for market dynamics and R&D catalysts in biopharma?

Outlook 2022 Growth

Infographic: Top 100 Pharma Companies

The Scrip 100 universe gathers FY 2020 financial performance data and compares the activities of the top 100 biopharma businesses, ranked by pharma sales. 

Outlook 2022 Commercial

Novartis Slips Into Pfizer's Number One Pharma Slot Amid Leaderboard Shakeup

Pfizer has dropped to number seven in our top pharma rankings after a long reign. AbbVie has risen to number three, growing through merger expansion.

Outlook 2022 Commercial

Innovation Explore this Topic

Set Alert for Innovation

Latest From Innovation

CES 2022: The Intersection Of Digital Health And Consumer Tech

CES 2022 was missing some marquee names due to the latest coronavirus surge, but there was still plenty to take in at the intersection of digital health and consumer tech. In this roundup, In Vivo highlights some standouts, with commentary from company leaders.

Diagnostics Cardiology

‘Bugs As Drugs’ Approach To Cancer Nears Advanced Development

Microbiome modulators, known mainly for development in infectious and gastrointestinal diseases, could prove an asset in oncology thanks to the work of biotechs.

ImmunoOncology Companies

Olympus Medical Follows The Patient Pathway In New Strategic Plan

Having divested non-medical imaging a year ago, Olympus Corp is putting its foot to the floor in refocusing on its medical portfolio. It has set global ambitions of strengthening its coverage of unmet needs and of playing a major role in reshaping health care delivery.

Commercial Medical Device
Data Spotlight

Alzheimer’s Disease: Many Failures Before One Success

For Biogen/Eisai’s success with Aduhelm, there were 93 failures in the anti-amyloid field. In Vivo's sister publication Scrip took a look back at how the pipeline for amyloid-targeting Alzheimer’s drugs progressed over the past decade to showcase exactly how difficult the Alzheimer’s space has been.

Boehringer Ingelheim: 1885 To Present

Founded in 1885 by Albert Boehringer and now comprised of 146 affiliated companies worldwide and a workforce of roughly 50,000 people, Boehringer Ingelheim has stood the test of time.

Titans Of Pharma 2021: J&J’s Gorsky Tops Big Pharma Remuneration

A snapshot of the compensation packages of CEOs and R&D leaders of the world’s biggest pharmaceutical companies, alongside median employee pay and key company performance metrics.

Leadership Explore this Topic

Set Alert for Leadership

Latest From Leadership

J.P. Morgan Highlights: Major M&A Missing, But Key Takeaways For Year Ahead

The annual J.P. Morgan Health Care Conference has come to a close. In Vivo has summarized some of the key themes to appear from 2022’s meeting of industry leaders, investors and technology creators.

Business Strategies Commercial

Execs On The Move, December 2021

An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.

BioPharmaceutical Medical Device

Industry And Investors Ponder Legacy Of Theranos Scandal

What lessons can be learned from the conviction of Theranos founder Elizabeth Holmes, found guilty on four counts of investor fraud in a US court on 4 January?

Commercial Financing

Market Access Explore this Topic

Set Alert for Market Access

Latest From Market Access

Pharma Versus Hospitals: 340B Battle Continues

Exploring the continued controversy around the 340B US federal drug discount program. As the story moves into 2022, key questions remain unanswered.

Market Access Policy

Germany’s New Government Will Maintain Price Freeze And Slash Free Pricing Period

Big changes are in store on the drug pricing front in Germany. Further reforms could depend on who is appointed health minister.

Europe Germany

US Biosimilars Enjoy A Year Of Firsts In 2021

While US biosimilar approvals have been thin on the ground in 2021 – with products delayed due to the FDA’s inability to conduct certain facility inspections during the COVID-19 pandemic – the market has nevertheless seen several firsts this year, including two interchangeability designations and the first ophthalmic biosimilar approval.

Outlook 2022 Market Access

Market Intelligence Explore this Topic

Set Alert for Market Intelligence

Latest From Market Intelligence

Deals In Depth: December 2021

Eight $1bn+ alliances were penned in December. Topping the list was a potential $12.4bn deal between Recursion and Roche (and its Genentech subsidiary) involving the identification and development of small-molecule programs in a gastrointestinal cancer indication and in key areas of neuroscience. Recursion is responsible for creating a certain number of PhenoMaps, which are massive relational databases of biological and chemical perturbation phenotypes. For each of the PhenoMaps requested by Roche, Recursion may be subject to an initiation fee up to $250m for sixteen accepted PhenoMaps. Recursion will receive an up-front payment of $150m and is eligible for additional performance-based research milestones. Roche and Genentech have the option to obtain an exclusive license to initiate up to 40 programs, each of which, if successfully developed and commercialized, could yield more than $300m in development, commercialization, and sales milestones for Recursion.

Deals Financing

In Vivo’s Deals Of The Year 2021: Cast Your Vote!

It is time for In Vivo's 14th annual Deals of the Year contest. We've selected 15 nominees across three categories – Top Alliance, Top Financing and Top M&A – and you get to pick the winners.

Deals M & A

Deals Shaping The Medical Industry, December, 2021

In Vivo's Deal-Making column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in December 2021. Data provided by Biomedtracker

BioPharmaceutical Medical Device
UsernamePublicRestriction

Register